Bailard’s PMV Pharmaceuticals PMVP Stock Holding History

Bailard’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,069	Closed	-$21.3K	–	803
2025 Q4	$21.3K	Buy	+17,069	New	+$22.9K	﹤0.01%	744

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bailard's PMVP Position: Q1 2026 in Review

Bailard sold out of PMV Pharmaceuticals (PMVP) in Q1 2026, closing a stake of 17,069 shares — an estimated $21.3K sold.

Bailard first reported a position in PMVP in Q4 2025 and held it in 1 quarter. The position peaked at $21.3K in Q4 2025. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

Bailard reported no remaining PMV Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bailard sold 17,069 PMV Pharmaceuticals shares in Q1 2026, an estimated $21.3K.
Bailard first reported a position in PMV Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Bailard's PMV Pharmaceuticals position peaked at $21.3K in Q4 2025.
69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.